About / the publisher
About this PT-141 digest
A tiered ledger of the published bremelanotide literature and the approved label — and a plain statement of what it is not.
What Meds PT-141 is
Meds PT-141 keeps an evidence ledger of the peer-reviewed research literature and the approved drug label on PT-141 (bremelanotide). No clinician is on staff; no one here is advised or treated; nothing is manufactured, stocked, or sold. The pages read the record and tier it — they are not a service.
The "meds" in the name is editorial framing — a position this publisher occupies relative to the literature on an approved medication, not a claim that the site provides medications, treatment, consultation, or prescriptions. It does none of those things. It reads the record and reports it.
Is PT-141 FDA-approved?
Yes, for one indication. Bremelanotide was approved by the FDA on June 21, 2019 (NDA 210557) as a subcutaneous injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. It is not approved for men, for postmenopausal women, for erectile dysfunction, or to enhance sexual performance — every use beyond the single approved indication is off-label and rests on early-phase or investigational data [6][14]. Material sold as "PT-141 research chemical" sits outside that approval framework entirely, with no regulatory oversight of its identity, purity, or concentration.
One further status note: melanocortin receptor agonists fall under the World Anti-Doping Agency's non-approved-substances framework (S0) in the relevant context, so athletes should consult current WADA guidance directly. PT-141 is not a US controlled or scheduled substance.
How we handle the record
Two principles govern this ledger. First, evidence tiers stay visible: the FDA label and the peer-reviewed Phase 3 trials carry the most weight, conference abstracts and corporate press releases are flagged as lower-tier, and the findings that complicate the picture (including a 2025 negative preclinical result) are reported alongside the supportive ones [10]. Second, the cited clinical record and informal community reports are kept in separate, clearly-labeled layers — anything anecdotal is marked as unverified and is never attributed to a study. Doses are summarized only as documented findings, and none is recommended. Every quantitative claim links to a source in the studies and references.
The ledger is also plain about the limits of what is known. The strongest evidence concerns one population and one indication; the male, erectile, postmenopausal, and weight-related threads are early-phase or off-label, and each is labeled that way every time it appears rather than letting interest in a topic inflate the certainty of the data behind it [14]. Where a finding is a single conference abstract, the page says so. Where a number comes from a corporate pipeline announcement, it is treated as a development status and not a result. The aim is a record a careful reader can trust precisely because it does not oversell — the bright surface of this site is a reading instrument, never a sales page, and the negative space between "approved for this" and "studied for that" is kept visible on purpose.